Thursday, March 13, 2025 10:40:20 AM
Trying to wrap my head around a few things from the financials. First, does this look correct? (especially US revenues)
..................U.S...................EU...................RoW................Other/Licensing Fee.......Total
Q1 2024....48,100,000.......1,900,000.........5,200,000.........1,300,000.....................56,500,000
Q2 2024....43,800,000.......3,500,000.........200,000............20,000,000...................67,500,000
Q3 2024....30,600,000.......4,300,000.........6,900,000.........500,000........................42,300,000
Q4 2024....44,200,000.......4,000,000........11,900,000........2,200,000.....................60,100,000
Total.........166,700,000.....13,700,000........24,200,000.......24,000,000...................228,600,000
I'm trying to understand two things:
1. How did we go from $30M US revs in Q3 to $44M US revs Q4, when script count went DOWN? Is this just a timing issue between quarters? The average between the two quarters would seem to make sense (~37.5M avg).
2. WHAT is going on in Europe?? How are revenues flat/down from Q3 to Q4? That seems illogical. Is this again some sort of timing issue, and Q1 will look great?
EDIT: Sorry for the formatting. Can't seem to make it look better than that.
..................U.S...................EU...................RoW................Other/Licensing Fee.......Total
Q1 2024....48,100,000.......1,900,000.........5,200,000.........1,300,000.....................56,500,000
Q2 2024....43,800,000.......3,500,000.........200,000............20,000,000...................67,500,000
Q3 2024....30,600,000.......4,300,000.........6,900,000.........500,000........................42,300,000
Q4 2024....44,200,000.......4,000,000........11,900,000........2,200,000.....................60,100,000
Total.........166,700,000.....13,700,000........24,200,000.......24,000,000...................228,600,000
I'm trying to understand two things:
1. How did we go from $30M US revs in Q3 to $44M US revs Q4, when script count went DOWN? Is this just a timing issue between quarters? The average between the two quarters would seem to make sense (~37.5M avg).
2. WHAT is going on in Europe?? How are revenues flat/down from Q3 to Q4? That seems illogical. Is this again some sort of timing issue, and Q1 will look great?
EDIT: Sorry for the formatting. Can't seem to make it look better than that.
Recent AMRN News
- Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN) • IH Market News • 05/27/2026 03:24:38 PM
- New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
